research use only

Bradykinin

Name: Bradykinin
Brand: Selleck Chemicals
SKU: E0037
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.E0037

Bradykinin is a potent vasodilator peptide that exerts its vasodilatory action through stimulation of specific endothelial B2 receptors, thereby causing the release of prostacyclin, NO, and EDHF.

Chemical Structure

Molecular Weight: 1060.21

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Batch: E003701 DMSO]100 mg/mL]false]Water]100 mg/mL]false]Ethanol]Insoluble]false Purity: 99.95%

99.95

Related Targets	Dyes Antineoplastic and Immunosuppressive Antibiotics ADC Cytotoxin PROTAC Selection Antibiotics for Transfected Cell Antibiotics for Mammalian Cell Culture ADC Linker Antibiotics for Plant Cell Culture PROTAC Linker Hydrotropic Agents Antibody-Drug Conjugate E3 ligase Ligand Target Protein Ligand Molecular Glues Enzyme Substrate Drug-Linker Conjugates for ADC Surfactant Chelating Agent
Related Products	BAPTA-AM Rat IgG2b isotype control-InVivo Blebbistatin Methyl-β-cyclodextrin (MβCD) AP-III-a4 (ENOblock) Carbazochrome sodium sulfonate (AC-17) Ursolic Acid Osthole 4-Methylumbelliferone (4-MU) Dioscin Ethidium bromide Sesamin Bilobalide Formononetin Hesperidin L-Mimosine Carbenoxolone Sodium Vitexin N6022 Dp44mT Chlorogenic Acid Sphingosine Chrysin Coenzyme Q10 (CoQ10) Spermine Tetrahydrochloride 2-NBDG D-Lin-MC3-DMA (MC3) Morin Hydrate Ethylenediaminetetraacetic acid Silibinin (NSC 651520)

Chemical Information, Storage & Stability

Molecular Weight	1060.21	Formula	C₅₀H₇₃N₁₅O₁₁	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	58-82-2	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)N2CCCC2C(=O)NCC(=O)NC(CC3=CC=CC=C3)C(=O)NC(CO)C(=O)N4CCCC4C(=O)NC(CC5=CC=CC=C5)C(=O)NC(CCCN=C(N)N)C(O)=O

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (94.32 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 100 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

References	[1] https://pubmed.ncbi.nlm.nih.gov/9054837/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06109142	Not yet recruiting	Critically Ill Patients	Assistance Publique - Hôpitaux de Paris	April 1 2024	--
NCT06210698	Not yet recruiting	Angioedema\|Angioedemas Hereditary\|Urticaria\|Mastocytosis\|ACE Inhibitor-Induced Angioedema\|C1 Inhibitor Deficiency\|Systemic Mastocytoses\|Indolent Systemic Mastocytosis	Foundation For Rare Disease Research\|Institute for Asthma & Allergy\|Virant Diagnostics Inc.\|MedBio Reference Laboratories Inc.	January 15 2024	--
NCT06380699	Completed	Acute Ischemic Stroke	Changzhou Qianhong Bio-pharma Co. Ltd.	March 16 2023	Phase 1
NCT05304091	Unknown status	Bradykinin-mediated Angioedema	University Hospital Lille	August 2022	--
NCT04763577	Recruiting	Angio-Oedema Caused by Angiotensin-Converting-Enzyme Inhibitor	University Hospital Grenoble\|University Hospital Paris\|University Hospital Rouen	October 27 2021	--

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):